Fax: (901) 521-9005
Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia
Article first published online: 7 MAR 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 8, pages 1654–1658, 15 April 2007
How to Cite
Madden, R. M., Pui, C.-H., Hughes, W. T., Flynn, P. M. and Leung, W. (2007), Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer, 109: 1654–1658. doi: 10.1002/cncr.22562
- Issue published online: 4 APR 2007
- Article first published online: 7 MAR 2007
- Manuscript Accepted: 2 JAN 2007
- Manuscript Revised: 29 DEC 2006
- Manuscript Received: 10 NOV 2006
- National Institutes of Health. Grant Number: CA21765
- American Lebanese Syrian Association Charities (ALSAC)
- Pneumocystis carinii;
- opportunistic infection;
Despite extensive studies of atovaquone in human immunodeficiency virus (HIV)-infected patients, there is little information about its efficacy as a prophylactic agent for Pneumocystis carinii pneumonia (PCP) in pediatric patients with cancer. Therefore, a retrospective analysis was conducted to determine the incidence of PCP in pediatric patients who received prophylactic atovaquone during treatment for acute leukemia.
We reviewed the medical records of all patients treated at our institution for acute lymphoblastic leukemia or acute myeloid leukemia between 1994 and 2004. Only patients who were intolerant of trimethoprim-sulfamethoxazole (TMP-SMZ) and received atovaquone prophylaxis were included in the analysis.
Eighty-six patients were unable to tolerate TMP-SMZ and received daily atovaquone for PCP prophylaxis. PCP was not diagnosed in any patient who received atovaquone prophylaxis: the upper limit of the 95% confidence interval (CI) was 1.74 per 100 person-years.
Atovaquone is an efficacious alternative for PCP prophylaxis in pediatric patients who have leukemia and are intolerant of TMP-SMZ. Cancer 2007. © 2007 American Cancer Society.